[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]. [electronic resource]
Producer: 20110113Description: 163-71 p. digitalISSN:- 0048-7449
- Alendronate -- adverse effects
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Bone Remodeling -- drug effects
- Clinical Trials as Topic -- statistics & numerical data
- Denosumab
- Drug Delivery Systems
- Female
- Fracture Healing -- drug effects
- Fractures, Spontaneous -- etiology
- Humans
- Immunosuppressive Agents -- administration & dosage
- Injections, Subcutaneous
- Models, Biological
- Multicenter Studies as Topic -- statistics & numerical data
- Osteoclasts -- drug effects
- Osteonecrosis -- chemically induced
- Osteoporosis, Postmenopausal -- complications
- Patient Compliance
- RANK Ligand -- administration & dosage
- Receptor Activator of Nuclear Factor-kappa B -- physiology
No physical items for this record
Publication Type: English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.